The Street.com flunks its own geography test! Congrats to Cubist and all shareholders.
FDA Approves Cubicin, Previously Cidecin, an Antibiotic Developed by Cubist Pharmaceuticals
Friday September 12, 6:15 pm ET
The Only Once-Daily, Rapidly Bactericidal Antibiotic Proven Effective Against Both MRSA and MSSA
LEXINGTON, Mass.--(BUSINESS WIRE)--Sept. 12, 2003-- Cubist Pharmaceuticals, Inc. (Nasdaq: CBST - News) today announced that the U.S. Food & Drug Administration (FDA) has approved Cubicin(TM) (daptomycin for injection; previously known as Cidecin®) for the treatment of complicated skin and skin structure (cSSS) infections caused by Gram-positive bacteria, including those caused by MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-susceptible S. aureus). Cubist anticipates the product to be available to physicians and hospitals by early November.
"The approval of CUBICIN is particularly important as we face the growing public health crisis of bacterial resistance," said Robert A. Weinstein, MD, Chairman of the Division of Infectious Diseases at Stroger Hospital of Cook County in Chicago and a Cubist scientific advisor. "There has been a frightening increase in MRSA infections over the past decade, and the tools currently available to combat this problem have become less effective. The approval of CUBICIN gives physicians a new weapon against cSSS infections, particularly to treat the estimated 600,000 U.S. patients who contract MRSA cSSS infections each year." |
